Mizuho raises Boston Scientific target to $130, maintains Outperform
Securities adjusted its outlook on Boston Scientific (NYSE:BSX) shares, raising the price target to $130 from $110 while maintaining an Outperform rating. The revision follows a series of positive developments reported by the medical device company,
Boston Scientific price target raised to $118 from $111 at Barclays
Barclays raised the firm’s price target on Boston Scientific (BSX) to $118 from $111 and keeps an Overweight rating on the shares. The firm
Which Is a Better Investment, Boston Scientific Corporation or Penumbra, Inc. Stock?
Learn more about whether Boston Scientific Corporation or Penumbra, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
Stifel raises Boston Scientific stock target to $120, keeps buy rating
Stifel analysts increased their price target on Boston Scientific Corporation (NYSE:BSX) shares from $115.00 to $120.00, while reiterating a Buy rating for the medical device company. The adjustment follows recent meetings that left analysts with a positive outlook on the company's future financial performance.
Boston Scientific price target raised to $120 from $115 at Stifel
Stifel raised the firm’s price target on Boston Scientific (BSX) to $120 from $115 and keeps a Buy rating on the shares after having hosted
Boston Scientific (BSX) is a Great Momentum Stock: Should You Buy?
Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher.
Truist lifts Boston Scientific stock target to $120, maintains Buy
Truist Securities expressed a positive outlook on Boston Scientific (NYSE:BSX) shares, raising the price target to $120 from $110, while reaffirming a Buy rating. The stock, currently trading near its 52-week high of $107.
Truist Financial Sticks to Their Buy Rating for Boston Scientific (BSX)
Truist Financial analyst Richard Newitter maintained a Buy rating on Boston Scientific (BSX – Research Report) today and set a price target of
Q4 Earnings Review: Medical Devices & Supplies - Diversified Stocks Led by Boston Scientific (NYSE:BSX)
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...
GlobalData on MSN4d
Farapulse boosts Boston Scientific’s Q4 electrophysiology sales by 172%
Boston Scientific is reaping the rewards from the energised PFA market opportunity in atrial fibrillation treatment.
MassDevice5d
Boston Scientific expects double-digit sales growth in 2025 following Street-beating Q4
Boston Scientific (NYSE: BSX) shares ticked up slightly before hours today on fourth-quarter results that beat the consensus ...
Boston Scientific Co. (NYSE:BSX) Given Consensus Recommendation of “Buy” by Brokerages
Boston Scientific Co. (NYSE:BSX – Get Free Report) has been given an average recommendation of “Buy” by the twenty-three ...
FierceBiotech5d
Boston Scientific clocks over $1B in Farapulse revenue for the afib therapy's first year
Boston Scientific apparently knows a good bet when it sees one. | That includes treating more than 200,000 patients with the irregular heartbeat known as atrial fibrillation—and the sum more than ...
Reuters5d
Boston Scientific sees higher-than-expected 2025 profit on strong demand
Feb 5 (Reuters) - Medical device maker Boston Scientific (BSX.N), opens new tab forecast annual profit above Wall Street estimates on Wednesday, banking on steady demand for its heart devices.
Boston Scientific (NYSE:BSX) Given New $115.00 Price Target at Stifel Nicolaus
Boston Scientific (NYSE:BSX – Get Free Report) had its price objective hoisted by research analysts at Stifel Nicolaus from ...
medtechdive5d
Boston Scientific closes its year of PFA on a high note
Farapulse, Boston Scientific’s pulsed field ablation product, fueled year-over-year growth of nearly 171% in the fourth ...